We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 07, 2020

Nivolumab With SBRT vs Nivolumab Alone in Metastatic HNSCC

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
J. Clin. Oncol 2020 Aug 21;[EPub Ahead of Print], S McBride, E Sherman, CJ Tsai, S Baxi, J Aghalar, J Eng, WI Zhi, D McFarland, LS Michel, R Young, R Lefkowitz, D Spielsinger, Z Zhang, J Flynn, L Dunn, A Ho, N Riaz, D Pfister, N Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading